Partial results of a huge, real-world study of Medtronic’s (NYSE:MDT) superDimension LungGPS technology found that 65% of patients diagnosed with primary lung cancer (Stages I and II) were at early stages of the disease. Early detection of lung cancer is critical to improving patient outcomes long-term. The results came from a 12-month follow-up of the 1,215-patient […]
Clinical Trials
Acutus Medical touts 12-month AcQMap-guided AF ablation trial data
Acutus Medical today released 12-month data from the Uncover-AF trial of its AcQMap cardiac imaging and mapping system exploring its use in persistent atrial fibrillation ablation procedures. Results from the trial were presented at the 24th Annual AF Symposium in Boston, the Carlsbad, Calif.-based company said. Acutus Medical’s AcQMap system is designed to detect and […]
Neovasc jumps on Tiara trial news
Neovasc (NSDQ:NVCN) said today that it won approval to advance a clinical trial for its Tiara transcatheter mitral valve replacement, sending its share price up on Wall Street. The Vancouver-based company said it closed out the Phase I requirements for the 115-patient Tiara-II trial in the U.K. and Germany, after several reviews. The Clinical Events Committee […]
InspireMD touts results of ‘one-size-fits-all’ stroke-prevention study
A clinical trial of InspireMD’s (NYSE:NSPR) CGuard embolic prevention stent showed that it successfully treated patients whose carotid arteries varied in size, according to the company. The investigator-initiated trial in Germany used a 10 mm diameter CGuard stent with SmartFit technology across a broad range of carotid artery diameters. Variations in diameters of the common carotid artery (CCA) […]
Boston Scientific touts 4-year Rezūm BPH treatment trial data
Boston Scientific (NYSE:BSX) last Friday released results from a clinical trial of its Rezūm benign prostatic hyperplasia device, touting durable results and the preservation of sexual function at four years post-treatment. Results from the trial are set to be published in the journal Urology, and have already been published online, the Marlborough, Mass.-based company said. “This […]
Gore touts 12-month Tigris stent study data
W.L. Gore & Associates today released 12-month results from a registry study of its Gore Tigris vascular stent designed to treat peripheral artery disease in the superficial femoral artery and proximal popliteal artery, touting that the device was shown to be safe and effective. Results from the trial were presented at the LINC 2019 meeting […]
CorMatrix wins FDA IDE approval for Cor Tricuspid ECM cardiac valve trial
CorMatrix Cardiovascular said today that it won FDA investigational device exemption approval to launch an early feasibility study of its Cor Tricuspid ECM cardiac valve intended for treating adults with endocarditis and pediatric patients with congenital heart valve disease. The Atlanta-based company touts its Cor Tricuspid valve as the first cardiac valve of its kind […]
Neovasc touts Reducer study
Neovasc (NSDQ:NVCN) this week touted a newly-published article that described the use of dipyridamole stress perfusion cardiac magnetic resonance to evaluate its Reducer device. The Vancouver-based company’s device is designed to treat refractory angina. The article, published in the Journal of the American College of Cardiology: Cardiovascular Interventions, featured a 66 year old man with angina who […]
Abbott touts effective pain management, lower energy use in BurstDR SCS study results
Abbott (NYSE:ABT) late last week released results from a study of its BurstDR spinal cord stimulation technology, touting that it provided as effective pain relief as standard SCS despite providing lower-energy, intermittent stimulation known as “microdosing,” for patients with chronic intractable pain. Results from the BOLD study were presented at the 22nd Annual North American Neuromodulation […]
Boston Scientific’s Vici venous stent meets primary endpoints at 1 year
Boston Scientific (NYSE:BSX) today touted 12-month data for its Vici venous stent in people with significant obstructions in the illiofemoral venous outflow tract. Researchers reported that the Vici stent met its primary efficacy endpoint with a primary patency rate of 84% at one year. Nearly 99% of people treated with the Vici stent were free from […]
LINC 2019: Medtronic, Boston Scientific back paclitaxel devices amid safety probe
Amid concerns about a potential link between paclitaxel devices and heightened long-term mortality rates, Medtronic (NYSE:MDT) and other device-makers doubled down on their products’ safety at this year’s Leipzig Interventional Course in Germany. Medtronic presented a patient-level survival analysis that included 1,837 patients enrolled in its In.Pact Admiral clinical program. Get the full story at our sister […]